c-Jun N-terminal kinase (JNK) is implicated in various human diseases, including cancer, inflammatory disorders, and neurodegeneration. JNK inhibitor IX is a potent JNK inhibitor with pIC50 values of 6.5 and 6.7 for JNK2 and JNK3, respectively[3]. Pre-treatment of human dermal fibroblasts with JNK inhibitor IX (10μM) 30min before chromium exposure significantly reduces caspase-3 activity compared to the group only treated with chromium[4]. Treatment of myeloid cells with JNK inhibitor IX (10μM) for 24 h significantly reduced JNK phosphorylation and increased apoptotic cell death in response to imatinib mesylate[5].
作用机制
JNK inhibitor IX is a potent, ATP-competitive inhibitor of both JNK2 and JNK3[3].
TCS JNK 5a 细胞实验
Cell Line
Concentration
Treated Time
Description
References
Human CD34+ cells
0.1 μM
10 days
Used to test the effect on hematopoietic stem cell expansion. The results showed that the inhibitor significantly increased the frequency and number of CD34+CD45RA− cells compared with DMSO-treated control cells
Cell Discov. 2019 Jan 8;5:2.
IMR90 human diploid fibroblasts
0.5 μM
4 days
induced spotty nuclear morphology and cellular senescence
Mol Biol Cell. 2015 Sep 1;26(17):2971-85.
Mouse spermatogonial stem cells
3 μM
6 days
To inhibit JNK signaling pathway and study its effect on spermatogonial stem cell proliferation. Results showed that JNK Inhibitor IX significantly suppressed spermatogonial stem cell proliferation.
Stem Cell Reports. 2015 Mar 10;4(3):489-502.
HepG2 cells
10 μM
7 days
To test the effect of JNK-IN-5A on TAG accumulation in DNL and OA steatosis models. Results showed that JNK-IN-5A significantly reduced TAG accumulation in the DNL model but had no significant effect on the OA model.
搜索
